Breast Cancer Risk Prediction Using a Polygenic Risk Score in the Familial Setting: a Prospective Study from the Breast Cancer Family Registry and KConFab
Overview
Authors
Affiliations
Purpose: This study examined the utility of sets of single-nucleotide polymorphisms (SNPs) in familial but non-BRCA-associated breast cancer (BC).
Methods: We derived a polygenic risk score (PRS) based on 24 known BC risk SNPs for 4,365 women from the Breast Cancer Family Registry and Kathleen Cuningham Consortium Foundation for Research into Familial Breast Cancer familial BC cohorts. We compared scores for women based on cancer status at baseline; 2,599 women unaffected at enrollment were followed-up for an average of 7.4 years. Cox proportional hazards regression was used to analyze the association of PRS with BC risk. The BOADICEA risk prediction algorithm was used to measure risk based on family history alone.
Results: The mean PRS at baseline was 2.25 (SD, 0.35) for affected women and was 2.17 (SD, 0.35) for unaffected women from combined cohorts (P < 10). During follow-up, 205 BC cases occurred. The hazard ratios for continuous PRS (per SD) and upper versus lower quintiles were 1.38 (95% confidence interval: 1.22-1.56) and 3.18 (95% confidence interval: 1.84-5.23) respectively. Based on their PRS-based predicted risk, management for up to 23% of women could be altered.
Conclusion: Including BC-associated SNPs in risk assessment can provide more accurate risk prediction than family history alone and can influence recommendations for cancer screening and prevention modalities for high-risk women.Genet Med 19 1, 30-35.
McInerny S, Mascarenhas L, Yanes T, Petelin L, Chenevix-Trench G, Southey M BMJ Open. 2024; 14(8):e087874.
PMID: 39107016 PMC: 11308879. DOI: 10.1136/bmjopen-2024-087874.
Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women.
Mars N, Kerminen S, Tamlander M, Pirinen M, Jakkula E, Aaltonen K J Clin Oncol. 2024; 42(13):1477-1487.
PMID: 38422475 PMC: 11095905. DOI: 10.1200/JCO.23.00295.
Cardone K, Dudek S, Keat K, Bradford Y, Cindi Z, Daar E Pac Symp Biocomput. 2023; 29:594-610.
PMID: 38160309 PMC: 10764076.
Liu T, Liao C, Chang Y, Chen Y, Chen H, Lai I Int J Mol Sci. 2023; 24(22).
PMID: 38003606 PMC: 10671380. DOI: 10.3390/ijms242216417.
Polygenic risk scores: the future of cancer risk prediction, screening, and precision prevention.
Wang Y, Zhu M, Ma H, Shen H Med Rev (2021). 2023; 1(2):129-149.
PMID: 37724297 PMC: 10471106. DOI: 10.1515/mr-2021-0025.